发明名称 Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
摘要 Described herein are compositions and methods of treating and/or preventing inner ear conditions by administering to a patient in need thereof a modulator of a metabotropic glutamate receptor.
申请公布号 US9173864(B2) 申请公布日期 2015.11.03
申请号 US200913124883 申请日期 2009.10.19
申请人 House Ear Institute 发明人 Friedman Rick;Vollrath Benedikt
分类号 A61K31/4192;A61K31/44;A61K31/198;A61K9/00;A61K9/06;A61K31/4523;A61K31/4545 主分类号 A61K31/4192
代理机构 Nixon Peabody LLP 代理人 Huber Linda B.;Nixon Peabody LLP
主权项 1. A method for treating inner ear conditions associated with or characterized by aberrant glutamatergic signaling in the inner ear, comprising administration of a pharmaceutical composition comprising an amount of a modulator of a Group I mGluR sufficient to treat the conditions, wherein the composition is a controlled release gel formulation administered on or near the round window membrane of the inner ear, wherein the modulator of a Group I mGluR is 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC), and wherein the inner ear condition is selected from excitotoxicity, presbycusis, tinnitus, and noise-induced hearing loss.
地址 Los Angeles CA US